For US Healthcare Professionals
RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS*
ACR20 response at Week 24 after just 4 doses (primary endpoint) and an OLE active treatment NRI post hoc analysis from Weeks 24 to 1001-6
EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS*
Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA1-6
PROVEN SAFETY PROFILE IN PSORIATIC DISEASE†
Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA1
ROBUST‡ COVERAGE
& DEDICATED PATIENT SUPPORT
Commercial coverage as strong as Humira® (adalimumab)—no step edit required7§||¶